These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22869571)

  • 1. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
    Stryjewski ME; Potgieter PD; Li YP; Barriere SL; Churukian A; Kingsley J; Corey GR;
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5476-83. PubMed ID: 22869571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
    Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
    Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
    Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
    Prince WT; Ivezic-Schoenfeld Z; Lell C; Tack KJ; Novak R; Obermayr F; Talbot GH
    Antimicrob Agents Chemother; 2013 May; 57(5):2087-94. PubMed ID: 23422913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.
    Noel GJ; Draper MP; Hait H; Tanaka SK; Arbeit RD
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5650-4. PubMed ID: 22908151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
    Friedland HD; O'Neal T; Biek D; Eckburg PB; Rank DR; Llorens L; Smith A; Witherell GW; Laudano JB; Thye D
    Antimicrob Agents Chemother; 2012 May; 56(5):2231-6. PubMed ID: 22314524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
    Hegde SS; Okusanya OO; Skinner R; Shaw JP; Obedencio G; Ambrose PG; Blais J; Bhavnani SM
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
    Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
    Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
    J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
    Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA
    Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
    Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.